Estrella Immunopharma (ESLA) Total Debt (2022 - 2026)

Estrella Immunopharma (ESLA) has reported Total Debt for 4 consecutive years, with $687224.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Debt rose 265.66% year-over-year to $687224.0 in Q2 2026; TTM through Jun 2026 was $687224.0, a 265.66% increase from a year earlier, with the FY2025 full-year figure at $356505.0, changed N/A from the prior year.
• Total Debt was $687224.0 for Q2 2026 at Estrella Immunopharma, up from $465132.0 in the prior quarter.
• Over five years, Total Debt peaked at $687224.0 in Q2 2026 and troughed at $50000.0 in Q4 2022.
• A 4-year average of $334035.6 and a median of $328252.5 in 2023 frame the typical range for Total Debt.
• Across the five-year window, Total Debt plunged 39.83% in 2023 and surged 265.66% in 2026, its largest moves.
• Over 4 years, Total Debt stood at $50000.0 in 2022, then jumped by 500.0% to $300000.0 in 2023, then rose by 18.83% to $356505.0 in 2025, then surged by 92.77% to $687224.0 in 2026.
• The last three Total Debt figures came in at $687224.0 (Q2 2026), $465132.0 (Q1 2026), and $356505.0 (Q4 2025), per Business Quant data.